Scienture Holdings, Inc. (Nasdaq: SCNX) announced entering into a securities purchase agreement with institutional investors.
The agreement involves the purchase of 3,225,000 shares of common stock at $1.20 per share in a registered direct offering.
Gross proceeds from the offering are expected to be around $3.9 million before deducting fees and expenses.
The offering is set to close on August 15, 2025, subject to customary conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share
Gross Proceeds
Approximately $3.9 million before deductions
Placement Agent
Maxim Group LLC is the sole placement agent in the offering
Registration Statement
Offering is made under Form S-3 (File No. 333-289198) declared effective on August 8, 2025
Prospectus Availability
Prospectus supplement and accompanying prospectus will be available on the SEC's website and through Maxim Group LLC.
- The agreement will provide significant funds to Scienture Holdings for its operations and development.
- This move showcases investor confidence in Scienture's business model and growth potential.
The securities purchase agreement marks a strategic step for Scienture Holdings, reinforcing its position in the pharmaceutical market.